# OnCo record paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019" ;
  schema:name "PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study"@en ;
  schema:alternateName "AHL2011"@en, "Casasnovas 2019"@en ;
  schema:description "Starting with the most intensive Hodgkin chemotherapy and switching to the gentler standard once the scan cleared gave the same disease control with far less anaemia, bleeding risk and infection."@en ;
  schema:url <https://onco.cc/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(18)30784-8>, <https://pubmed.ncbi.nlm.nih.gov/30658935/>, <https://europepmc.org/article/MED/30658935> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30784-8> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Casasnovas RO, Bouabdallah R, Brice P, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/imaging/> ;
  onco:technologies <https://onco.cc/technologies/pet-ct/> ;
  onco:drugs <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/> ;
  onco:companies <https://onco.cc/companies/lysa/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/non-inferiority/> ;
  onco:trials <https://onco.cc/trials/ahl2011/>, <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/rathl/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .